Form 4 for CRL Charles River Laboratories
Accepted 2023-05-17 00:00:00 ET · period of report 2023-05-15 · accession 0001127602-23-015850 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-05-17 | 2023-05-15 | CRL | MACKAY MARTIN | Dir | A - Grant | $0.00 | +664 | 11.2K | +6% | $0 |
| D | 2023-05-17 | 2023-05-15 | CRL | MACKAY MARTIN | Dir | A - Grant | $192.36 | +1,669 | 1,669 | New | +$321.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-15 | A | A | 664 | $0.00 | 11,167 | D | — | — | (F1) The unvested restricted stock units vest upon the earlier of 5/15/2024 or the business day prior to the Company's next annual meeting of shareholders. |
| 2 | Derivative | Stock Options (Right to Buy) | 2023-05-15 | A | A | 1,669 | $192.36 | 1,669 | D | $192.36 · 2024-05-15 to 2033-05-15 | 1,669 Common Stock | (F2) The Stock Options become exercisable upon the earlier of 5/15/2024 or the business day prior to the Company's next annual meeting of shareholders. |